Free Submission Public Relations &
Deutsch English


Hyperuricemia - Pipeline Review, H2 2013 - New Report Available

Print article Print article
2013-12-19 12:22:53 - New Pharmaceuticals market report from Global Markets Direct: "Hyperuricemia - Pipeline Review, H2 2013"

Global Markets Direct's, 'Hyperuricemia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hyperuricemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hyperuricemia. Hyperuricemia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Full Report Details at

- ..


* A snapshot of the global therapeutic scenario for Hyperuricemia.
* A review of the Hyperuricemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Hyperuricemia pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to Get this Report

* Identify and understand important and diverse types of therapeutics under development for Hyperuricemia.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Hyperuricemia pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned in this Report: AstraZeneca PLC, Teijin Pharma Limited, Chugai Pharmaceutical Co. Ltd, Kissei Pharmaceutical Co., Ltd., Nippon Chemiphar Co., Ltd., Polaris Group

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Global Markets Direct Report Coverage
Hyperuricemia Overview
Therapeutics Development
An Overview of Pipeline Products for Hyperuricemia
Hyperuricemia Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Hyperuricemia Therapeutics - Products under Development by Companies
Companies Involved in Hyperuricemia Therapeutics Development
AstraZeneca PLC
Teijin Pharma Limited
Chugai Pharmaceutical Co. Ltd
Kissei Pharmaceutical Co., Ltd.
Nippon Chemiphar Co., Ltd.
Polaris Group
Hyperuricemia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
lesinurad - Drug Profile
Product Description
Mechanism of Action
R&D Progress
arhalofenate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Uricase-PEG 20 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
febuxostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KUX-1151 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NC-2500 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KGO-2142 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KGO-2173 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JPH-367 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
UR-1102 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hyperuricemia Therapeutics - Drug Profile Updates
Hyperuricemia Therapeutics - Discontinued Products
Hyperuricemia Therapeutics - Dormant Products
Hyperuricemia - Product Development Milestones
Featured News & Press Releases
Nov 01, 2013: Mylan Confirms First-to-File Patent Challenge Relating to Uloric
Apr 11, 2012: Teijin Pharma And Menarini Sign Distribution Agreement For Marketing Of Febuxostat
Dec 08, 2011: Metabolex Announces Positive Results From Clinical Study Of Arhalofenate In Combination With Febuxostat
Jul 28, 2011: Teijin Pharma Launches Febuxostat In Korea
May 13, 2011: Teijin Pharma To Launch FEBURIC In Japan
Apr 18, 2011: Teijin Pharma Expands Global Market For TMX-67
Jan 21, 2011: Teijin Pharma Receives Approval Of TMX-67 For Treating Hyperuricemia In Japan
Oct 27, 2010: Teijin Pharma Launches TMX-67 In Canada
Mar 09, 2010: Menarini Launches ADENURIC (Febuxostat) In Europe
Mar 05, 2010: Launch by Menarini and Ipsen of Adenuric (febuxostat) in France for the treatment of chronic hyperuricemia in gout
Secondary Research
Primary Research
Expert Panel Validation
Contact Us

List of Tables
Number of Products Under Development for Hyperuricemia, H2 2013
Products under Development for Hyperuricemia - Comparative Analysis, H2 2013

Full Table of Contents is available at:

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Bill Thompson
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News


Terms & Conditions | Privacy | About us | Contact | BidVertiser